Trial reportTransfusion2012
Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.
Trial report in Transfusion, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 66 citations in OpenAlex.
- Article
- Identification of human parvovirus 4 genotypes 1 and 2 in Chinese source plasma pools.Journal of medical virology · 2021Article
- Parvovirus 4 in Individuals with Severe Hemophilia A and Matched Control Group.International journal of hematology-oncology and stem cell research · 2021Article
- Human Parvoviruses May Affect the Development and Clinical Course of Meningitis and Meningoencephalitis.Brain sciences · 2020Article
- Human Parvovirus 4: A harmless bystander or a pathogen of severe acute respiratory illness.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Human parvovirus B19 and parvovirus 4 among Iranian patients with hemophilia.Blood research · 2017Article
- Human Parvoviruses.Clinical microbiology reviews · 2017Review
- Human parvovirus 4 'PARV4' remains elusive despite a decade of study.F1000Research · 2017Review
- Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.Emerging infectious diseases · 2016Article
- Human parvovirus 4 infection among mothers and children in South Africa.Emerging infectious diseases · 2015Article
- Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.Blood transfusion = Trasfusione del sangue · 2015Review
- Innovative approach for improved rFVIII concentrate.European journal of haematology · 2014Review
- PARV4: an emerging tetraparvovirus.PLoS pathogens · 2014Review
- Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.Transfusion · 2014Review
- Article
- Evolution of CD8+ T cell responses after acute PARV4 infection.Journal of virology · 2013Article
- Treatment of hemophilia B: focus on recombinant factor IX.Biologics : targets & therapy · 2013Article
- Human parvovirus 4 in nasal and fecal specimens from children, Ghana.Emerging infectious diseases · 2012Article
- Human parvovirus 4 viremia in young children, Ghana.Emerging infectious diseases · 2012Article
- Acute diarrhea in West African children: diverse enteric viruses and a novel parvovirus genus.Journal of virology · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundHuman parvovirus 4 (PARV4) is a newly discovered parvovirus prevalent in injecting drug users and other groups with histories of parenteral exposure including persons with hemophilia exposed to non-virally inactivated clotting factor concentrates. To investigate its potential ongoing transmission to persons with hemophilia treated with plasma-derived, virally inactivated clotting factors, we screened a large cohort of persons with hemophilia for antibody seroconversion to PARV4 over a 5-year observation period. STUDY DESIGN AND
methodsSamples from 195 persons with hemophilia enrolled in the Hemophilia Growth and Development Study cohort were screened for PARV4 antibodies at the start and end of a 5-year period of treatment with exclusively virally inactivated clotting factor concentrates. Samples collected at intermediate time points from subjects seroconverting over the study period were screened to narrow down the seroconversion time and investigate immunoglobulin (Ig)M responses, duration of acute viremia, and clinical presentations.
resultsPARV4 seroprevalence at the outset of the study was 44%. Over the observation period, nine subjects (seven human immunodeficiency virus positive) seroconverted for anti-PARV4 (incidence, 1.7%/year). Infected subjects showed relatively prolonged durations of viremia (mean, 7 months) and weak, transient IgM responses during acute infections. Clotting factors inactivated by solvent/detergent or by wet or dry heat were infectious. The most common clinical presentations were rashes and exacerbation of hepatitis.
conclusionThis study identifies PARV4 as a transfusion-transmissible agent that is resistant to viral inactivation. Of concern, infections may still regularly occur in those exposed to plasma-derived blood products. Urgent evaluation of the incidence of PARV4 in treated individuals and disease associations of PARV4 infections is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.